The less active enantiomer of Bay 41-4109 is primarily utilized in research settings to study its interaction with biological targets, particularly in the context of hepatitis B virus (HBV) replication. It serves as a valuable control compound in pharmacological studies to compare the efficacy and mechanisms of the more active enantiomer. By understanding its behavior, researchers can gain insights into the stereospecificity of drug action and optimize the design of antiviral agents. Additionally, it aids in elucidating the structure-activity relationship (SAR) of related compounds, contributing to the development of more effective therapeutic strategies against HBV.